Literature DB >> 7910717

Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease.

V Perfetti1, V Bellotti, A Maggi, E Arbustini, F De Benedetti, M Paulli, M G Marinone, G Merlini.   

Abstract

The patient (TAL), a chronic asymptomatic HBV carrier with HBsAg-anti-HBsAg circulating immune complexes, was admitted to our hospital because of a nephrotic syndrome due to renal amyloidosis. There was no family history of hereditary amyloidosis. Recurrent arthralgias, asthenia, and weight loss were the prominent clinical features. Laboratory test results showing that severe chronic inflammatory activity had been present for 6 years. Interleukin-6 (IL-6) serum concentration was 10 times normal and C-reactive protein was 1.9 mg/ml. A complex immunological picture was also present (immune complex formation, exuberant B-cell reactivity, and decrease in the number of CD4 T cells). A localized form of Castleman's disease (CD) (plasma-cell type) was diagnosed by surgical excision of a giant axillary lymph node. AA amyloid was present in the blood vessels. Within 60 days after excision of the mass, the systemic symptoms subsided, laboratory signs of inflammatory activity disappeared and IL-6 serum concentration returned to normal, thus establishing a causal relationship between the localized Castleman's disease, elevated IL-6 concentration and the chronic inflammation responsible for AA amyloidosis. At 10 months of follow-up, the nephrotic syndrome has reversed, kidney function has slowly ameliorated, and the patient has gained 12 kg. Abdominal fat aspirates drawn to search for amyloid, positive before surgery, were subsequently negative. The latter finding, and the remission of the nephrotic syndrome, provided strong evidence for regression of the amyloid deposits. However, the HBsAg-anti-HBsAg immune complexes and depression of T-helper cell activity persist. This immunological derangement is therefore not a consequence of CD. Chronic stimulation of the immune system due to the patient's inability to eliminate HBV, in the contest of perturbed immunity, may have favored the genesis of the lymphadenopathy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910717     DOI: 10.1002/ajh.2830460306

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

Review 1.  Anti-amyloid drugs: potential in the treatment of diseases associated with aging.

Authors:  R Kisilevsky
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 2.  Renal complications of Castleman's disease: report of two cases and analysis of 75 cases.

Authors:  Xiang-Gui Yuan; Wen Hu; Fei-Fei Chen; Bin-Feng Huang; Xiao-Ying Zhao
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

3.  Systemic reactive amyloidosis associated with Castleman's disease: serial changes of the concentrations of acute phase serum amyloid A and interleukin 6 in serum.

Authors:  S Ikeda; H Chisuwa; S Kawasaki; J Ozawa; Y Hoshii; T Yokota; T Aoi
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

4.  Grand rounds--Hammersmith Hospital. Reactive (AA) systemic amyloidosis. A cause of refractory nephrotic syndrome.

Authors: 
Journal:  BMJ       Date:  1996-04-27

5.  Marked hepatomegaly due to AA type amyloidosis in a case with Castleman's disease.

Authors:  Noboru Yamagata; Jyunko Fujio; Risen Hirai; Mutsumi Matsumaru; Satoshi Tanimura; Chiho Inokuchi; Tateki Shikai; Naoki Takezako; Michiyo Nasu; Yoichi Sakata; Naohiro Sata; Hideo Nagai; Ken Saito; Akiyoshi Miwa
Journal:  Int J Hematol       Date:  2006-07       Impact factor: 2.490

Review 6.  An autopsy case of multicentric Castleman's disease associated with interstitial nephritis and secondary AA amyloidosis.

Authors:  Yuriko Morita-Hoshi; Shuji Tohda; Osamu Miura; Nobuo Nara
Journal:  Int J Hematol       Date:  2007-12-08       Impact factor: 2.490

Review 7.  Treatment of Castleman's disease.

Authors:  Angela Dispenzieri; Morie A Gertz
Journal:  Curr Treat Options Oncol       Date:  2005-05

8.  HHV-8-negative multicentric Castleman disease presenting as a crescentic immune complexes membranoproliferative glomerulonephritis.

Authors:  Maria Brito Nunes; Samuel Rotman; Francois-Regis Duss; Matthieu Halfon
Journal:  BMJ Case Rep       Date:  2020-01-06

Review 9.  AA amyloidosis associated with Castleman disease: A case report and review of the literature.

Authors:  Luca Bernabei; Adam Waxman; Gabriel Caponetti; David C Fajgenbaum; Brendan M Weiss
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.